Treatment for ovarian cancer normally involves a combination of chemotherapy and surgery. Chemotherapy uses special medicines to kill or shrink the cancer cells. Drugs used to treat ovarian cancer are considered systemic therapies.
Market Dynamics
High prevalence of ovarian cancer is expected to propel growth of the ovarian cancer drugs market. For instance, the National Cancer Institute estimated around 22,530 new cases of ovarian cancer and 13,980 deaths due to the disease in the U.S. in 2019. Moreover, availability of effective drugs is also expected to aid in growth of the market. For instance, in October 2020, according to a new research conducted by scientists at the Fox Chase Cancer Center and Gynecologic Oncology Group, a targeted medication known as bevacizumab, also going by the name Avastin, may delay the development of advanced ovarian cancer.
R&D in ovarian cancer is expected to offer lucrative growth opportunities for players in the ovarian cancer drugs market. For instance, in June 2020, a study presented via the virtual Society of Gynecologic Oncology 2020 Annual Meeting on Women's Cancer, reported examining a large clinical dataset of low-grade serous ovarian cancer through the Ovarian Cancer Association Consortium, with the primary goal of identifying factors that affect survival.
However, development of vaccines is expected to hinder growth of the ovarian cancer drugs market. For instance, in December 2020, Anixa Biosciences entered into a license agreement with Cleveland Clinic for exclusive, world-wide rights to an ovarian cancer vaccine technology.
Major players operating in the ovarian cancer drugs market are focused on R&D to expand their product portfolio. For instance, in December 2020, TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, announced positive interim data from the ongoing Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors in ovarian cancer.
Competitive Analysis
Major players operating in the ovarian cancer drugs market include, Bristol Myers Squibb Company, Eli Lilly and Company, IMV Inc., TCR2 Therapeutics Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, and F. Hoffman-La Roche Ltd.
Major players operating in the ovarian cancer drugs market are focused on R&D to expand their product portfolio. For instance, in December 2020, IMV Inc., a clinical-stage biopharmaceutical company, reported updated clinical and translational data from DeCidE1, its Phase 2 clinical study evaluating the safety and efficacy of DPX-Survivac with intermittent low-dose cyclophosphamide (CPA) in patients with recurrent, advanced platinum-sensitive and platinum-resistant ovarian cancer.
No comments:
Post a Comment